Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers outline ferroptosis mechanisms and regulatory networks in lung cancer, highlighting potential therapeutic targets. The study suggests ferroptosis as a novel approach to overcome treatment resistance in lung cancer, providing hope for improving clinical outcomes.
A new therapy combines gene-modified dendritic cells with immunotherapy to promote a stronger immune response against lung cancer. The treatment slows down tumor growth and activates T cells to attack cancer cells systemically.
A Mount Sinai study found that primary care physicians' approach to selecting patients with comorbidities for lung cancer screening is influenced by subjective clinical judgments. The researchers recommend streamlined protocols and clearer guidelines to increase adoption of lung cancer screening for this high-risk population.
Patients with multimorbidity and limited life expectancy are often unaware of the potential harms of lung cancer screening. Despite this, many agree to undergo screening due to personal health goals, trust in their clinician, and anticipation of regret over not getting screened. Discussions between patients and clinicians about the ben...
Primary care physicians struggle to balance harms and benefits of lung cancer screening in patients with multiple health issues, often relying on clinical judgment. Ultimately, the decision rests with the patient, who makes their own choice despite physician advice.
Developed by scientists from the University of Oxford, the LungVax vaccine uses technology similar to the highly successful Oxford/AstraZeneca COVID-19 vaccine. The vaccine will train the immune system to recognise and attack abnormal lung cells with neoantigens.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
A new study from Johns Hopkins Medicine found that circulating tumor DNA levels can accurately assess how gastroesophageal cancers respond to treatment and predict future prognosis. The study tracked minimal residual disease by analyzing ctDNA, showing a correlation between ctDNA clearance and cancer-free survival.
Researchers at Massachusetts General Hospital have discovered a network of immune cells, called stem-immunity hubs, that are associated with a favorable response to immunotherapy in non-small cell lung cancer. The presence of these hubs can serve as a biomarker to predict response to treatment.
Scientists at Johns Hopkins have developed a novel approach to identify cancer-causing repeats in DNA sequences, enabling non-invasive detection and monitoring of cancers. The ARTEMIS method uses machine learning to analyze cell-free DNA and distinguish between tumor and normal tissues with high accuracy.
A study by Cancer Research UK reveals that mortality rates have dropped by 37% in men and 33% in women, with significant reductions in cervical cancer and lung cancer. However, cancer cases are on the rise overall, and researchers warn of an immense challenge ahead to maintain progress.
Researchers found that patients recovering from robotic lung surgery do not fully recover even after 90 days, despite common expectations. The study suggests a more thoughtful approach to pre-surgery communication with patients is needed to better understand their recovery experiences.
Researchers discovered that lung cancer cells can persist in the presence of cigarette smoke due to a protein pump called ABCG2, which clears damaging molecules from the cells. This mechanism could also contribute to resistance to pharmaceutical treatments in cancer cells.
Researchers analyzed access to new treatments for early-stage lung cancer in Europe, highlighting existing disparities in healthcare systems and reimbursement structures. The study calls for a collective European approach to reduce inequalities in access to care.
A large-scale study has found a significant link between smoking and DNA methylation, with two new epigenetic markers identified that differ by race or ethnicity. The research could lead to better ways to predict smoking-related disease risk and improve early detection and treatment.
Researchers at the University of Pennsylvania have developed a new method to efficiently determine which lipid nanoparticles are likely to bind to the lungs, rather than the liver. This breakthrough enables targeted delivery of mRNA therapeutics beyond the liver, offering new hope for treatments of cystic fibrosis and lung cancer.
A new atlas of lung cells reveals transitional alveolar cell state harboring KRAS mutations in normal lung cells, which can lead to lung adenocarcinoma. This finding opens doors for developing new detection strategies.
Researchers at University at Buffalo propose a new approach to developing cancer drugs by determining the optimal placement of molecular linkers earlier in the process, reducing trial and error and increasing potency, according to a study published in Communications Chemistry.
Researchers found elevated radon gas levels in rural homes near drilled groundwater wells, with a 30% higher exposure risk compared to urban areas. Regular testing is crucial for mitigating radon-related lung cancer risks in rural communities.
A new genetic signature of 140 genes may predict enhanced disease-free survival in patients with non-small cell lung cancer treated with immunotherapy and low-dose radiation. The signature is associated with aggressive tumor growth but also increased immunity and tissue repair after treatment.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers found that Inuit residents in Nunavik had shorter survival rates for lung cancer compared to Montreal residents, despite similar disease stages. The study attributes this disparity to chronic under-resourcing of healthcare services and lack of Inuit representation in healthcare provision.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
A Phase II trial found that durvalumab plus ceralasertib provided the greatest clinical benefit in patients with immunotherapy-resistant non-small cell lung cancer, with improved overall survival and objective response rates. The combination showed a manageable safety profile.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
A study of 2.9 million Korean adults found that quitting smoking at any age reduced the risk of cancer, particularly lung cancer, after 10 years. Early cessation before middle age led to a substantial risk reduction in lung cancer.
The research group evaluated the on- and off-target effects of a self-assembled EGFR siRNA delivery system, finding potent interference with only 1/2000000 of synthetic transfection amount. Transcriptomic analysis revealed minimal off-target effects in normal tissues and significant anti-EGFR effects in tumor cells.
A new study found an association between radon exposure and an increased risk of stroke in middle-aged female participants. The study showed that even moderate concentrations of radon were linked to a higher risk of stroke compared to those exposed to lower concentrations.
Cancer kills more Black people than White individuals in the Barretos region, whereas in São Paulo city, it is the opposite, according to a study published in Cancer Causes & Control. The disparity is most pronounced for breast and cervical cancer among Black women.
Researchers developed a new chip that can detect cancer cells in blood samples, enabling clinicians to adapt treatments and improve outcomes for patients with lung cancer. The device traps and concentrates tiny numbers of cancer cells, allowing for regular monitoring of treatment effectiveness.
Experts predict a significant increase in bowel cancer death rates among young adults in the EU and UK, driven by rising obesity and heavy alcohol consumption. Death rates are predicted to rise by 26% in men and nearly 39% in women in the UK, with similar increases seen in Italy and other European countries.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
A study from Dana-Farber Cancer Institute found that unintentional weight loss is associated with an increased risk of cancer diagnosis within the coming year. The research suggests that patients experiencing unexpected weight loss should see their doctor to consider possible causes, including cancer. Healthy weight loss can come from ...
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
A study of nearly 15,000 adults with non–small cell lung cancer found that Medicaid expansion decreased postoperative mortality within 30 and 90 days after hospital discharge. This suggests that expanded Medicaid coverage may improve cancer outcomes and access to care for this population.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
Researchers developed nanosensors that can be inhaled and detected in urine, offering a potential alternative to CT scans for early lung cancer detection. The diagnostic system shows high specificity and sensitivity in detecting stage 1 or 2 lung tumors.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
A survey of low-income adults showed a significant decrease in food insecurity, from 20.6% in 2019 to 15.5% in 2021. The findings highlight the importance of financial relief and nutritional benefits for vulnerable populations during the pandemic.
A study in the JAMA Network Open found that Hispanic and American Indian individuals with breast, colorectal, lung, and prostate cancer were undercaptured in the National Cancer Database, but representation improved over time. Further investigation is needed to understand where these populations seek cancer care.
The IASLC Early Detection & Screening Committee published a perspective outlining key components of LDCT screening regimens. The report emphasizes the need for data-driven management systems, quality assurance assessments, and multi-disciplinary clinical management to maximize benefits of early detection and treatment.
Researchers identified Benidipine as a compound promoting the death of cigarette smoke-induced senescent lung cells, improving lung emphysema. The dihydropyridine family of calcium channel blockers constitutes a new class of senolytics that could improve lung diseases.
A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Researchers have discovered that immune cells play a crucial role in directing the growth of human lung tissue during development, revolutionizing our understanding of early lung development. The findings also suggest that early immune disturbances could manifest as pediatric lung disease.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...
New research found that less than five minutes of daily physical activity can be beneficial for people living with inoperable lung cancer, reducing mortality rates by 60% compared to those who were largely inactive. Healthcare providers should investigate a person's levels of physical activity in early management of the disease.
Researchers identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer. Combining immunotherapy with dupilumab boosted patients' immune systems and showed significant tumor reduction in six out of six cases.
Researchers Haval Shirwan and Esma Yolcu design a molecule, SA-4-1BBL, that mobilizes immune cells to target cancer cells. The molecule shows promising results in preventing lung cancer by triggering the immune system's defense mechanism.
The Lung-MAP trial has demonstrated the potential of public-private partnerships in clinical research, increasing access to new treatment options for patients with lung cancer. The unique partnership between academia, advocacy, federal agencies, and industry has led to a more representative patient group being enrolled in clinical trials.
A new study finds that structural racism is a significant contributor to unequal lung cancer risk factors, affecting different racial and ethnic groups differently. The research highlights the need for tailored preventive interventions to address these disparities.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
A new study by Tulane University has identified a previously unknown molecular pathway that could halt lung cancer growth. The research found that protein RBM10 can suppress lung cancer by targeting the function of c-Myc, a protein that drives cancer cell growth and proliferation.